CONFERENCE BROCHURE

BIOMARKERS EUROPE 2024 & SPATIAL BIOLOGY EUROPE 2024

30 September - 01 October 2024 | Basel, Switzerland

The 3rd Annual **Biomarkers** & **Spatial Biology** Congresses will bring together over 500 key opinion leaders to share insights into biomarker approaches to accelerate timelines in drug development & precision oncology and delve into the most exciting developments in spatial research, technologies, & applications.

Complimentary Guest Passes Are Available

Book Now (Biomarkers)

Book Now (Spatial Biology)

Key Speakers Include

PHILIP BEER,
Step Pharma

DIRK KEMMING,
Daiichi Sankyo

DYLAN POWELLS,
University of Stirling

SEMIRAMIS POPOVA,
AstraZeneca

ROSALBA GIUGNO,
University of Verona

OLGA NISSAN,
Protica Bio

STÉPHANIE TISSOT,
Centre Hospitalier Universitaire Vaudois

FELIX SEGERER,
AstraZeneca

More Information:
oxfordglobal.com/biomarkers/events/biomarkers-europe-2024
oxfordglobal.com/omics/events/spatial-biology-europe-2024

@OGConferences

LinkedIn

WELCOME TO

Biomarkers Europe 2024 & Spatial Biology Europe 2024

Oxford Global are pleased to share with you the 2024 programme for the **3rd Annual Biomarkers Europe**, **2nd Annual Precision Oncology** & **3rd Annual Spatial Biology Congresses** in Basel, 30th September - 1st October 2024.

The utilisation of technology offered by spatial genomics has the potential to revolutionize precision medicine and biomarker research. To explore the most innovative technologies and approaches for biomarker validation, identification, and analysis, as well as applications in precision oncology and personalized patient treatment, Oxford Global is delighted to host two events showcasing the latest technologies and clinical studies in this exciting field.

To expand on the possibilities offered by spatial genomics, Oxford Global is proud to host our co-located Spatial Biology Europe Congress. This event is set to address the latest developments in spatial research including AI, bioinformatics, and exciting applications that are pushing the field towards the clinic. Don't miss out on attending this two-day congress where you will have a unique opportunity to discuss with key opinion leaders who are pushing the fields of spatial biology and biomarker research to the forefront of the healthcare industry.

Benefits to Attending

- **Acquire knowledge about how biomarker approaches are utilized in drug discovery** and translational sciences. Key opinion leaders will be covering areas such as the qualification of biomarkers for translational studies, assay development & multi-omics approaches.
- **Digital Health Development For Clinical Development** & Personalised Patient Treatment. Providing insights into clinical trials development and how these can support next generation of personalized patient treatment across Europe.
- **Learn about emerging bioanalysis approaches,** assay development, and what can be translated into the clinic.
- **Take a deep dive into image analysis and AI-powered imaging.** Key opinion leaders will be providing insights into computational image analysis, multiplexed digital pathology, and the utilisation of AI & machine learning within spatial transcriptomic studies.
- **Gain comprehensive insights into utilising spatial biology in pharma.** Hear about spatial research & spatial technologies in pharma R&D and also using the technology for diagnostics purposes & clinical development use cases.

BROCHURE CONTENTS

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn

@OGConferences

ATTENDEES

Network and Knowledge-share

500+ VPs, Directors & Senior Managers will be attending on-site and online, coming from leading healthcare, biotech, pharma and research institutions in the following fields and more:

- Translational Science
- Biomarker Discovery & Development
- Precision Medicine
- Multiplex Technology
- Preclinical Development
- Spatial Metabolomics
- Spatial Proteomics
- Computational Biology
- Image Analysis
- Molecular Medicine
- Precision Diagnostics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1-2-1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated refreshment (networking) breaks covering:

- Multiplex Tools
- Biomarker Validation
- Clinical Trial Solutions/ CROs
- Early Detection
- Precision Diagnostics
- Spatial/ Tissue Imaging Platforms
- Data Analysis Tools
- Spatial Profiling
- Spatial Bioinformatics
- Cytometry
- Translational Science
- Precision Medicine

Previous Attendee Profile

(Stats from Biomarkers & Precision Oncology Europe 2023)

25% - Manager/Senior
19% – Director
18% – Head/Lead
17% – Scientist
13% – C - Level

72% – Europe
23% – UK
3% – Rest of World
2% – US

50% – Industry
37% - Commercial
13% – Academic

Attended by these companies & many more:

AstraZeneca · NOVARTIS · Roche · Novo Nordisk Pharmatech A/S · novo nordisk · SERVIER · CANCER RESEARCH UK · UNIVERSITÄT MANNHEIM · ucb

Book Now (Biomarkers)

Book Now (Spatial Biology)

WHO IS SPONSORING?

Drive Innovation & Accelerate Research

Diamond Sponsors

nanoString A BRUKER COMPANY

ThermoFisher SCIENTIFIC

Platinum Sponsors

10x GENOMICS

Canopy BIOSCIENCES A BRUKER COMPANY

Gold Sponsors

labcorp

Lunaphore a biotechne brand

Personalis

PredxBio

STANDARD BIOTOOLS

somalogic

Silver Sponsors

abcam progress happens together

AKOYA BIOSCIENCES THE SPATIAL BIOLOGY COMPANY

ARC

CellCarta

DISCOVERY LIFE SCIENCES

Leica MICROSYSTEMS

Miltenyi Biotec

Navinci

Olink

PRECISION for medicine

PIXELGEN TECHNOLOGIES

RULES BASED MEDICINE an IQVIA business

SAPIENT

sengenics

seer

synexa Life Sciences

Ultivue Profiling Cancer Biology

Bronze Sponsors

ARDENA

ariadne.ai https://ariadne.ai

BIOGNOSYS NEXT GENERATION PROTEOMICS

CELLECTA

DIAGNEXIA ANALYTIX

HAWK Biosystems

ICON

RARECYTE

STANDARD BIOTOOLS

SURFIX diagnostics

Network & Programme Sponsors

ALMAC

BIOIVT

BioLizard

CONCEPT LIFE SCIENCES

CROWN BIOSCIENCE

FIRALIS MolecularPrecision

HOLOGIC Diagenode

KYMOS GROUP

mission bio

MSD

Propath The Spatial Biology CRO

Volition

SESSION TOPIC AREAS

Explore Curated & Insightful Content

Biomarkers Europe 2024 & Spatial Biology Europe 2024 features **2 days** of in-person cutting-edge presentations and knowledge-sharing. The event will include **over 50** industry insights, sponsored presentations & think tank roundtable discussions.

Day One | 30 September 2024

Conference Room 1: Biomarkers For Diagnostic & Clinical Development

- Biomarker technologies for diagnostics development
  - » Multiplexing
  - » Flow cytometry
  - » AI/ ML for biomarker data analysis
- Translating biomarker research from bench to bedside & back again
- Multi- omics approaches to diagnostics & precision medicine
- RNA diagnostic development and applications
- Transforming clinical development through biomarker driven clinical trial design
- Application of biomarker for evolving regulatory requirements
- Precision medicine case studies

Conference Room 2: Identification, Qualification & Validation of Biomarkers in Translational Studies

- Qualification of biomarkers for translational studies
- Efficacy and PK/PD biomarkers in drug development
- Regulation of biomarker analysis – what can be translated in the clinic
- Case studies in biomarker discovery and validation
- The role of safety and efficacy biomarkers
- Assay development & validation
- Translational biomarkers from preclinical to clinical phase studies

Conference Room 3: Multi-Cancer Early Detection Techniques & Companion Diagnostics for Precision Oncology

- Molecular characterization of tumour for targeted therapy selection
- Biomarker and companion diagnostic discovery and development
- Multi-cancer early detection, advanced diagnostics, & population screening
- Multi-cancer early detection and minimal residual disease testing
- Liquid biopsy biomarker development and implementation for precision oncology
- AI- assisted diagnosis for early detection of cancer
- Use of cellular, transcriptomic and proteomic biomarkers in clinical trials

Conference Room 4: Spatial Multi Omics Techniques & Approaches

- Translating spatial imaging techniques & approaches into clinics
- Transcriptomics, metabolomics & proteomics: techniques & approaches
- Single-cell transcriptome imaging
- Multi-modality processing

Conference Room 5: Image Analysis, AI-Powered Imaging & Digital Pathology for Spatial Biology

- Label free imaging technologies – imaging mass spec
- Accelerating the discovery of novel biomarkers and drug targets using spatial imaging
- Tissue imaging and analysis using advanced spatial profiling techniques
- Algorithm design for spatial data
- Imaging data analysis / how to set a spatial experiment
- Relevant spatial parameters in different model systems

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn

@OGConferences

SESSION TOPIC AREAS

Explore Curated & Insightful Content

Day Two | 01 October 2024

Conference Room 1:
Data-Driven Approaches for Biomarker Analysis in Drug Development

- Using digital biomarker to inform clinical decisions
- Digital Endpoints
- Addressing the gap between AI, RWE & Biomarker Data Analysis
- Approach for identifying drug sensitivity biomarkers across diverse data types for patient selection
- AI/ ML biomarker methods and data tools
- Optimizing clinical development programs
- Advanced approaches to bioanalysis
- Bioinformatics Tools in Biomarker Data Analysis
- Standardization of clinical digital biomarker data

Conference Room 2:
Biomarkers For Clinical Development & Personalised Patient Treatment

- Bench to bedside and back again
- Digital pathology on biomarker patient profiling
- Integration of trials, labs and data sciences to drive faster clinical development
- Digital health technologies for personalized patient treatment
- AI/ML technology to advance clinical development
  - » Big data analysis
- Clinical trials development and how these can support next generation of personalized patient treatment across Europe
- Genomics-enabled clinical trials for tailored cancer drug development
- Driving the implementation of precision medicine in oncology

Conference Room 3: Spatial Bioinformatics, Data Analytics and Interpretation

- Utilizing spatial data in biology
- Cell-cell interactions
- Overcoming the challenges in spatial data analysis
- Data integration & visualisation
- Spatial transcriptomic datasets
- Data access & standardization
- How do you translate AI/ML approaches into the clinical trials
- Data handling / generating insights

Conference Room 4: Applications of Spatial Research & Technologies in Biology

- Case studies from the areas of:
  - » Cardiovascular diseases
  - » Regenerative medicine
  - » Oncology
  - » Neurobiology & neurodegenerative diseases
  - » Infectious diseases
  - » Immunological diseases

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn
@OGConferences

MEET THE KEY SPEAKERS

Connect with Industry Influencers

Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees. Presentation highlights for Biomarkers Europe & Spatial Biology Europe 2024 include.

BRIAN LOCKHART, Global Head Of Companion Diagnostics, Servier Monde

Day One	
08:30	The Long & Winding Road From A Biomarker To An Approved Companion Diagnostic

DIRK KEMMING, Regional Medical Director Diagnostics, Daiichi Sankyo

Day One	
08:55	Turning Biomarkers Into Precision Medicine

FELIX SEGERER, Associate Director, Image Analysis, AstraZeneca

Day One	
08:55	Image Analysis Workflows for Multiplexed Digital Pathology In The Age Of Deep Learning

SEMIRAMIS POPOVA, Senior Scientist, AstraZeneca

Day Two	
15:55	Unlocking Immune Subpopulations Through Spatial Multi-Omics

SHASHANK SARAN, Associate Director, Translational Medicine Oncology, AstraZeneca

Day One	
09:45	Pharmacodynamic & Predicitve Biomarkers For Preclinical Evaluation Of Antibody Drug Conjugates

NOLWEN GUIGAL- Stephan, Head of Clinical Biomarkers, Servier

Day One	
14:35	Circulating Tumor DNA As A Key Biomarker For Oncology Phase I Clinical Drug Development

KATY VANDEREYKEN, Research Manager, KU Leuven

Day One	
08:55	Spatial Multi-Omics To Advance Biomedical Research

ASAD JAN, Assistant Professor, Arhus University

Day Two	
09:45	Molecular Signatures Of Altered Energy Metabolism & Circadian Rythm Perturbations In A Prion-Like Model Of Syncleinopathy

Programme Highlights

Interactive Sessions

- Workshop: Applications of Spatial Metabolomics
- Workshop: Spatial Identification Techniques to Advance Therapeutics
- Panel Discussion: How To Bridge The Gap Between The Bench & Bedside: Applications of Precision Medicine In A Healthcare Setting

Key Presentations

- Unlocking Cellular Complexity Through Multiplexed Immunofluorescence
- 3D Quantitative Imaging Of Bone Marrow Microenvironment
- Harnessing The Value Of Digital Biomarkers: Why We Need To 'Watch The Whole Movie Not Just The Trailer'
- Advancing Cancer Immunotherapy: AI-Enhanced Proteomics for Predictive Biomarkers

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn

@OGConferences

CONFIRMED SPEAKERS: DAY ONE

Gain Expertise from Thought Leaders

CHRISTIAN RUIZ
University Of Basel, Moonlight AI

BRIAN LOCKHART
Global Head Of Companion Diagnostics, Servier Monde

CHRISTIAN MÜNCH
Endowed Lichtenberg Professor for Molecular Systems Medicine, University of Frankfurt

DIRK KEMMING
Regional Medical Director Diagnostics, Daiichi Sankyo

OLGA NISSAN
Chief Executive Officer, Protica Bio

SHASHANK SARAN
Associate Director, Translational Medicine Oncology, AstraZeneca

JOANNA JANUS
Research Manager (Early Detection & Prevention), Cancer Research UK

KATY VANDEREYKEN
Research Manager, KU Leuven

FELIX SEGERER
Associate Director, Image Analysis, AstraZeneca

BERNHARD REIS
Biomarker lead, Roche

MAXIMILIAN BREITNER
Lab Head Clinical Bioanalytics, Sandoz

THIBAULT COURTELLEMONT
Senior Scientist, EPFL

AITANA SOGORB ESTEVE,
Senior Research Fellow, University College London

CAROLINA OSES
Researcher, SciLifeLab

CARSTEN HOPF
Professor, Mannheim University

JUN FREDERIKSEN,
Director of Omics Technologies, Novo Nordisk

MARISCA MARIAN,
MD Oncology Access Strategy Lead, Bayer

MERRICK STROTTON,
Principal Scientist, UCB

JOHAN SWINNEN,
Professor, KU Leuven

THOMAS HACH,
Senior Clinical Development Medical Director, Novartis

ED SCHUURING,
Clinical Scientist in Molecular Pathology, University Medical Cantre Groningen

DANIEL KEITLEY,
Research Scientist, Novo Nordisk

VAIA STAVROPOULOU,
Clinical Biomarker Lead, Molecular Partners

AMANDA HELSGRAVE,
Senior Research Fellow, University College London

CORNELIA WILSON,
Senior Lecturer, Canterbury Christ Church University

NOLWEN GUIGAL- STEPHAN,
Head of Clinical Biomarkers, Servier

JAN CHRISTOPH BRASE,
Translational Science Leader, Bayer

KRISTOFFER STAAL ROHBERG,
Clinical Associate Professor, Region Hovedstaden

JEHAD CHARO,
Biomarker & Experimental Medicine Leader, Roche

ZEINAB MOKHARTI,
Scientific Investigator, GSK

MATTHEW HUMPHRIES
Director of Research Operations, Leeds Teaching Hospitals NHS Trust

DANA MUSTAFA,
Assistant Professor & Group Leader, Erasmus University Medical Center

MALLESWARI CHALLAGUNDLA,
Laboratory Head, QTAS_Biomarkers, Abbvie

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn
@OGConferences

CONFIRMED SPEAKERS: DAY TWO

Gain Expertise from Thought Leaders

GUNTHER JANSEN
Senior Director, Head of Multimodal Data & Analytics, Novartis

GUILLAUME DESACHY
Head Of Biometrics, Pierre Fabre

STÉPHANIE TISSOT
Head of Immune Landscape Laboratory, Centre Hospitalier Universitaire Vaudois

DYLAN POWELL
Assistant Professor in Public Health & Innovation, University of Stirling

ALAIN VAN GOOL
Professor of Personalized Healthcare, Radboud University Medical Centre

RAPHAEL GOTTARDO
Professor & Director, Centre Hospitalier Universitaire Vaudois

DENIS SCHAPIRO
Group Leader, Heidelberg University Hospital

JACQUES COLINGE
Professor, University of Montpellier

PHILIP BEER
Chief Scientific Officer, Step Pharma

ASAD JAN
Assistant Professor, Arhus University

VAIA STAVROPOULOU
Clinical Biomarker Lead, Molecular Partners

IVAN GESTEIRA COSTA FILHO
Professor of Computational Genomics, University of Aachen

ANDREW R. JANOWCZYK
Assistant Professor, Emory University

THOMAS JENSEN
Chief Executive Officer, Allarity

ROSALBA GIUGNO
Professor, University of Verona

LASSE KRISTENSEN
Associate Professor & Group Leader, Aarhus University

CHRISTOPHE LE TOURNEAU
Professor, Curie Insitute

LÉO GUIGNARD
Group Leader, Aix-Marseille Université & CNRS, Institut of Developmental Biology of Marseille & Turing Centre for Living Systems, Marseille, France

CÉSAR NOMBELA-ARRIETA,
Associate Professor & Group Leader, University Hospital Zurich

HANNAH WILLIAMS,
Junior Group Leader, University of Bern

OLIVER BIEHLMAIER,
Head of Imaging Core Facility, University of Basel

SEMIRAMIS POPOVA,
Senior Scientist, AstraZeneca

MOHAMMAD ARASTOO,
Research Fellow, University Aberdeen

SINA NASSIRI,
Principal Bioinformatics Scientist & Team Lead, Roche

ALIYA SARMANOVA,
Clinical Development Lead Oncology & Genetics, Roche Diagnostics International

RANGANATH GUDIMELLA,
Bioinformatics Scientist, TRON Mainz

DAY ONE: 30 SEPTEMBER 2024

08:00 **Oxford Global's Welcome Address**

3RD ANNUAL BIOMARKERS EUROPE CONGRESS

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT

08:05

Plenary Keynote Address
The Long & Winding Road From A Biomarker To An Approved Companion Diagnostic: Experience From A Pharma Perspective

- The multiplex of factors influencing the development of companion diagnostic tests from the identification of a predictive biomarker, the global dynamics of IVD regulation, commercialization, technology evolutions, budget and development timelines through the lens of a mid-sized pharma

BRIAN LOCKHART, Global Head Of Companion Diagnostics,
Servier Monde

3RD ANNUAL SPATIAL BIOLOGY EUROPE CONGRESS

CONFERENCE ROOM 4: SPATIAL MULTI OMICS TECHNIQUES & APPROACHES

Plenary Keynote Address:
Combining Molecular & Global Information To Gain A Cell-Wide Understanding Of Cellular Changes Upon Stress

- Resolving spatiotemporal changes in the cellular proteome is necessary for building systems biology-based cellular models
- Developing and exploring quantitative proteomics models to monitor changes across organellar membrandes during stress and aging

CHRISTIAN MÜNCH, Endowed Lichtenberg Professor for Molecular Systems Medicine,
University of Frankfurt

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT

Track Chair: CHRISTIAN RUIZ, Chief Scientific Officer, MoonlightAI

08:30

Track Keynote Address: Turning Biomarkers Into Precision Medicine

- Clinical use of biomarkers in aiding patient identification

DIRK KEMMING, Head of Medical Affairs Oncology Europe and Canada,
Daiichi Sankyo

Streamlining Assay Development For Spatial Proteomics

- Overview of CellScape™ Precise Spatial Multiplexing technology and applications
- Discover how to streamline high-plex assay development for spatial biology workflows across cancer biology, immunology, and neuroscience using a hypothesis-driven approach

08:55

BENTON BERIGAN, Product Manager,
Canopy Biosciences, A Bruker Compamy

Advancing Cancer Immunotherapy: AI-Enhanced Proteomics For Predictive Biomarkers

- Introduction to Cancer Immunotherapy:
- Overview of H&N cancer and the role of immunotherapy
- Current challenges in preciting immunotherapy response
- The Importance of Early & Accurate Diagnosis:- significance of timley & precise identification of immunotherapy responders
- Innovations in Proteomics & AI:
- Deep dive into the proteomics technology & AI algorithms used
- Showcasing technological novelty & how it enhances sensitivity & reduces noise

09:20

OLGA NISSAN, Chief Executive Officer,
Protica Bio

CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

Track Chair: MALLESWARI CHALLAGUNDLA, Lab Head, AbbVie

Track Keynote Address: Integrating Biomarker Discovery & Qualification Into Research & Early Clinical Development: Successes, Lessons, & Many Open Questions

- The need for Novo Nordisk to integrate biomarker research into research & early clinical development
- How we currently conduct biomarker discovery & qualification with Novo Nordisk Research & Early Development
- Challenges we face and open questions to the community

JUN FREDERIKSEN,Director of Omics Technologies,
Novo Nordisk

Use Of Proximity Ligation Assays (PLA) To Enable Validation Of Antibodies For IHC Applications

- Validation of antibodies is an essential component of developing robust IHC-based assays
- Proximity ligation assays (PLA) can be effectively used to confirm expression patterns and select appropriate antibodies for IHC assay development

AMANDA WOODROOFFE, Senior Vice President,
Precision For Medicine

Pharmacodynamic & Predictive Biomarkers For Preclinical Evaluation Of Antibody Drug Conjugates

- Antibody–drug conjugates (ADC) are specifically designed to improve the delivery of chemotherapeutic agents by exploiting the target selectivity of mAbs
- AZD8205 is an ADC consisting of a human anti-B7-H4 antibody that is conjugated to a topoisomerase 1 inhibitor (TOP1i) warhead
- This presentation focuses on using IHC and digital image analysis methods to investigate the pharmacodynamics and mechanism of action of AZD8205 in preclinical models

SHASHANK SARAN, Associate Director, Translational Medicine Oncology,
AstraZeneca

CONFERENCE ROOM 3: MULTI-CANCER EARLY DETECTION TECHNIQUES & COMPANION DIAGNOSTICS FOR PRECISION ONCOLOGY

Track Chair: DANA MUSTAFA, Assistant Professor & Group Leader, Erasmus University Medical Center

Track Keynote Address: Patients With Cancer Access To Precision Oncology

- Precision medicine enables avoiding ineffective treatments through molecular profiling/ genomic testing in cancer patients
- Significant progress in understanding cancer biology has shifted drug development
- Precision oncology improves long-term survival, disease control, tolerability, and quality of life
- Do patients have access to precision oncology medicines and tumour profiling?
- The current situation in Europe, challenges, and solutions to improve patient access

MARISCA MARIAN, MD Oncology Access Strategy Lead,
Bayer

Facilitating Companion Diagnostics Studies To Reach Effective Personalized Medicine

- Deploying faster, agile trial designs including innovative early biomarker discovery to improve trial success rates
- Leveraging non-invasive liquid biopsies with sensitive NGS cell-free DNA for early stratification and retrospective biomarker exploratory analysis
- Using biomarker-informed strategies with a fit for purpose assay development based on intended use and regulatory requirements
- Facilitating companion diagnostics studies with partnerships, globally combinable data and specialized trial management teams

ALEXANDRE FORT, Lead Scientist,
Labcorp

From Discovery To Implementation Of Biomarkers For Cancer Early Detection: CRUK's Perspectives

- Introduction to Cancer Research UK
- CRUK strategy and support for cancer early detection and diagnosis
- Perspectives on MCEDs and engagement with the MCED field
- Biomarker R&D beyond MCEDs
- Opportunities for industry engagement and collaboration

JOANNA JANUS, Research Manager (Early Detection & Prevention),
Cancer Research UK

CONFERENCE ROOM 4: SPATIAL MULTI OMICS TECHNIQUES & APPROACHES

Track Chair: KATY VANDEREYKEN, Research Manager, KU Leueven

Track Keynote Address: Spatial Multi-Omics To Advance Biomedical Research

- Overview of the single-cell and spatial (multi-) omics capabilities at the KU Leuven Institute for Single Cell Omics (LISCO)
- How to choose the best technology for your research questions
- Examples of our latest applications to biomedical research

KATY VANDEREYKEN, Research Manager,
KU Leuven

Spatial Multi-Omics For Precision Target Identification In The Tumor Microenvironment

- This work introduces an innovative spatial multiomics methodology for the simultaneous analysis of RNA and protein within tumor tissuens
- The approach offers in-depth characterization of the tumor microenvironment, facilitating the discovery of critical biomarkers and therapeutic targets

DANIEL DOMINGUEZ AZORIN, Postdoctoral Fellow, Moor Lab, Department of Biosystems Science and Engineering,
ETH Zurich

Featured Session: Spatial Proteomics

Presentation 1: DIY Spatial Proteomics: Creative Solutions For An Affordable Pipeline

- Cost-effective setup using standard lab equipment
- Achieved identification of 8000 proteins per sample
- Validated with laser capture microscopy and FACS-sorted experiments

THIBAULT COURTELLEMONT, Senior Scientist,
EPFL

CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING & DIGITAL PATHOLOGY FOR SPATIAL BIOLOGY

Track Chair: CARSTEN HOPF, Professor, Mannheim University

Track Keynote Address: Image Analysis Pipeline For Multiplexed Digital Pathology In The Age Of Deep Learning

- Challenges in analyzing multiplexed digital pathology slides
- Our version of a scalable and robust IA pipeline for multiplexed digital pathology
- Examples of applied IA modules
- Maintaining the model zoo

FELIX SEGERER, Associate Director, Image Analysis,
AstraZeneca

T cell Activation & Cancer-Specific Phenotypes Discovered By The Molecular Pixelation 3D Proteomics Technology

- Immune cells rely on spatial reorganization of membrane proteins to carry out their functions
- MPX is a novel DNA sequencing-based technique that enables high-multiplex profiling of membrane protein abundance and spatial organization in single cells, revealing new phenotypes and potential biomarkers in blood cancer cells

LOUISE LEIJONANCKER, Field Application Scientist
Pixelgen Techologies

Delegates Are Welcome To Attend The Co-Located Sessions

3RD ANNUAL BIOMARKERS EUROPE CONGRESS		2ND ANNUAL PRECISION ONCOLOGY EUROPE CONGRESS	3RD ANNUAL SPATIAL BIOLOGY EUROPE CONGRESS	
CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3: MULTI-CANCER EARLY DETECTION TECHNIQUES & COMPANION DIAGNOSTICS FOR PRECISION ONCOLOGY	CONFERENCE ROOM 4: SPATIAL MULTI OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING & DIGITAL PATHOLOGY FOR SPATIAL BIOLOGY

09:45 **MORNING BREAK** | 1-2-1 Meetings x4 | Poster Displays

Modulation Of Proteomic Signatures By Ianalumab In Patients With Systemic Autoimmune Disease

- This presentation will examine the proteomic changes observed in patients with Sjögren's disease treated with ianalumab (VAY736), a monoclonal antibody targeting BAFFR
- Using the SomaScan® platform to measure over 7,000 proteins in serum and saliva samples, we identified pharmacodynamic signatures and potential biomarkers associated with treatment
- The findings provide insight into the biological effects of ianalumab and its potential implications for understanding disease mechanisms in Sjögren's disease

RAINER HILLENBRAND, Director, Biomarker Lead in Autoimmune Disease
Novartis

Advance Your Oncology Research With Validated Abcam Antibodies

- Your research deserves reliable antibodies. That's why, at Abcam, we're obsessed with validation
- We'll take you through the steps we use to validate our premium recombinant antibodies, including our groundbreaking biophysical quality control

ANTONELLA GALLI, Head of Characterization, Validation & Technical Quality ,
Abcam

Key Success Criteria for Successful Companion Diagnostic Development – A Global Central Laboratory Experience

- The Global Central Lab has played a key role in the development of Companion Diagnostics (CDx). Key success factors will be discussed underpinned by several case studies

ALAN WOOKEY, Vice President, Companion Diagnostics & Oncology,
IQVIA Laboratories

Access The Full Richness Of Biological Complexity With Single Cell And Spatial Multiomics

STEPHEN HAGUE, Senior Manager, Science & Technology Advisors
10x Genomics

SpaceIQ™: Revealing New Mechanisms of Action Harnessing Spatial Multi-Omics Powered by Spatial Computing

- The SpaceIQ™ platform employs an advanced probabilistic framework to analyze spatial multi-omics data, encompassing spatially resolved segmentation, spatially regularized continuous phenotyping, spatially organized microdomain discovery, and microdomain-specific network biology
- Through this comprehensive approach, SpaceIQ identifies functionally relevant transition cell states, discovers heterogeneous microdomains linked to disease progression, and elucidates intricate pathway interactions and signaling networks, including mechanisms of action
- This insightful process, powered by Explainable AI for mechanistic explanations, is pivotal in deciphering tumor dynamics from initiation to resistance, and in crafting robust spatial biomarkers for predicting therapy responses
- Our focus is to empower Pharma companies increase the probability of a successful definitive clinical trial through early phase patient enrichment using spatial biomarkers

B. DUSTY MAJUMDAR, Chief Executive Officer,
PredxBio

11:05

Applied Biomarker Multiplexing In Oncology Early Clinical Development

- Biomarkers and PD endpoints provide valuable and sensitive tools in drug development
- Challenges in developing a multiplex IF panel to investigate PD effects
- Example case showing IF-multiplex clinical biomarker results and how the data was used within the context of the project and clinical development

BERNHARD REIS, Biomarker Lead,
Roche

Automated Biomarker Assays In Biosimilar Development

- Biomarkers and PD endpoints provide valuable and sensitive tools in drug development
- This includes not only innovator drugs, but they also support biosimilar development
- This presentation offers an insight into how biomarkers can be used in this regard, from a bioanalytical point of view.

MAXIMILIAN BREITNER, Lab Head Clinical Bioanalytics,
Sandoz

Multi-Omic Profiling For Precision Oncology Development

- Characterising the tumor microenvironment
- Exploring precise location of immune cells in tissue samples

DANA MUSTAFA, Assistant Professor & Group Leader,
Erasmus University Medical Center

Featured Session: Spatial Proteomics

Presentation 2: Unlocking Cellular Complexity Through Multiplexed Immunofluorescence

- Let's delve into the realm of spatial proteomics and how it unveils the intricate cellular interactions within human tissue
- Showcasing the proficiency of our unit in multiplexed immunofluorescence, employing two cutting-edge instruments
- Tailored methods for multiplexing that elevate our understanding of spatial biology within the intricate tapestry of human tissues

CAROLINA OSES, Researcher,
SciLifeLab

Enabling High-Plex Image Analysis Across Spatial Platforms

- Users want to work with a variety of high-plex imaging platforms, then analyse, explore and share insights from their data
- In this talk I will share UCB's developing strategy to efficiently support these ambitions with common, platform agnostic tools (commercial and open source)
- Particular emphasis on open file formats (OME-NGFF/ZARR) and code (python/R) supported collaboration through user friendly data repositories (OMERO, cell x gene) and image viewer/analysis (Napari, QuPath) GUIs

MERRICK STROTTON, Principal Scientist,
UCB

11:30

Pathways To Digital Health: AI & Omics In Rheumatoid Arthritis

- Explore distinct protein and antibody profiles of rheumatoid arthritis (RA) integrated with clinical and immunological assessments.
- Understand the critical role of autoantibodies in monitoring disease progression and predicting treatment response in RA
- Discover how these molecular signatures underlie variability in RA histopathology, revealing key autoimmune mechanisms and paving the way for personalized treatments

ALLAN STENSBALLE, Associate Professor,
Aalborg University & Aalborg University Hospital

Discovery & Validation Of Novel Drug Targets & Biomarkers: Using Large-Scale Multi-Omics Data To Bridge The Translational Gap

- How next-generation mass spectrometry is enabling rapid, high throughput multi-omics biomarker discovery, measuring thousands of proteins, metabolites, and lipids in every sample, across thousands of samples at a time
- How this multi-omics data is integrated using AI/ML tools to derive actionable insights for advancing drug development – from identifying optimal drug targets to biomarkers of response
- How large-scale human data assets can be employed to rapidly validate biomarker discoveries in independent populations and accelerate translation

MO JAIN, Founder & Chief Executive Officer,
Sapient

How To Successfully Monitor A Companion Diagnostic In Your Oncology Drug Development Programme

- CDx study monitoring assures the rights, safety and welfare of study subjects and helps to ensure the highest quality data for programme decision-making/ regulatory submission
- Successful monitoring approaches follow a robust risk-based monitoring plan, ensuring consistent, timely review of site readiness and data/sample management
- Summary of ARC lessons learnt - our do's and dont's of CDx monitoring studies

LINDSEY BENNIE, Clinical Project Manager,
ARC Regulatory

Exploring Complex Tissue Microenvironments With CellScape™ Precise Spatial Multiplexing

- Overview of CellScape™ Precise Spatial Multiplexing technology and applications
- Discover how CellScape™ facilitates high-plex quantitative, single-cell spatial proteomics, enabling researchers to explore complex tissue microenvironments with unprecedented precision

RACHID EL MORABITI, Spatial Regional Account Manager,
Bruker Spatial Biology

Methods For Functional Understanding Of Proteins: In Situ Proximity Ligation Assay And The Rise Of Spatial Interactomics

- Learn how proximity-based technology enables development of precise biomarkers and their application across protein research stages, from discovery to clinical use
- Discover how in situ proximity ligation technology goes beyond immunohistochemistry and can work in conjunction with spatial multiplexing techniques to illuminate protein function at the immune cell and tumor interface
- Explore the potential of automated in situ proximity-based protein detection in pre-clinical and clinical research, focusing on immune checkpoints like PDL1-PD1 and other immune cell interaction markers

FELIPE OLIVEIRA, Field Application Scientist
Navinci

11:55

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn @OGConferences

	3RD ANNUAL BIOMARKERS EUROPE CONGRESS		2ND ANNUAL PRECISION ONCOLOGY EUROPE CONGRESS	3RD ANNUAL SPATIAL BIOLOGY EUROPE CONGRESS	
	CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3: MULTI-CANCER EARLY DETECTION TECHNIQUES & COMPANION DIAGNOSTICS FOR PRECISION ONCOLOGY	CONFERENCE ROOM 4: SPATIAL MULTI OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING & DIGITAL PATHOLOGY FOR SPATIAL BIOLOGY
12:20	**Lung Cancer Cross Talk & The Identification Of Small Molecule Stabilizers Of The NF-kB Complex** • Lung cancer is a devastating cancer with poor prognosis, no effective treatment and understanding of disease progression • Sortilin levels are deregulated in a number of human diseases, including neurological disorders and lung cancers. Sortilin has recently been identified as a critical regulator of the inflammatory response • In this study, we used artificial intelligence molecular screening to obtain a set of small molecule compounds predicted to target a binding site within the p50:p65/RelA:IκBa trimer complex CORNELIA WILSON, Senior Lecturer, **Canterbury Christ Church University**	**Landscape Of Fluid Biomarkers In The Frontotemporal Lobar Degeneration Spectrum** • Current biomarkers for FTLD • Discovery studies for FTLD • What does the future hold in the field of fluid biomarkers for FTLD? AITANA SOGORB ESTEVE, Senior Research Fellow, **UCL**	*Delegates Are Welcome To Attend The Co-Located Sessions*	**Roundtable Discussion 1: Repeating Sample Use For Multi-Omic Experiments** • Sustainability considerations for sample use • Reusing samples downstream for other applications **Moderator:** KATY VANDEREYKEN, Research Manager, **KU Leuven**	**Roundtable Discussion 2: Combining Different Spatial Multi-Omics Technologies** • Combining data from different spatial sequencing technologies • Value of a combined multi-omics approach **Moderator:** CAROLINA OSES, Researcher, **SciLifeLab**
12:45	**Capturing Biomarker Insights From Translational Research** • The benefits of translational research in early-stage testing • Which early insights can be used to define a robust clinical biomarker strategy • Understanding the mechanism of action, safety and efficacy of a candidate in a clinically relevant model NICHOLAS WOUDBERG, Scientific Director, **Synexa Life Sciences**	**From Biomarker To Companion Diagnostic** • Development of custom biomarker assays with a focus on fast startup, cost control, and commercial considerations to ensure that assays work well in Phase 1 and can be scaled up for use in Phase 3 and regulatory approval SCOTT REID, Vice President & Head of Companion Diagnostics, **Discovery Life Sciences**	**Utilization Of An Ultra-Sensitive MRD Assay To Overcome Challenges In Early Recurrence Detection** • NeXT Personal is an advanced tumor-informed liquid biopsy assay with superior sensitivity and specificity in measuring MRD • Ultrasensitive detection with this bespoke whole genome sequencing based assay improves detection of ctDNA at baseline and during follow-up with increased lead time over clinical relapse • Clinical case studies in lung and breast cancer establish a strong correlation of NeXT Personal MRD with patient outcome CHRISTELLE JOHNSON, Associate Director, Field Application Scientist, **Personalis**	**High-Plex Spatial Proteomics Workflow For Enhanced Breast Cancer Research** • Overview of advancements in spatial proteomic workflows • Insights into cellular interactions and phenotypes in tumor microenvironments • Enhanced Understanding of Immune Cell Interactions • Benefits of high-plex imaging for breast cancer specimen analysis NANCIE MOONEY, Scientist, **ThermoFisher Scientific**	**Ariadne.ai SPATIAL - Cloud Based Spatial Omics Analysis** • Introducing SPATIAL: from pre-processing to statistical analysis. No coding, no specialized hardware required. Best-in-class registration and segmentation accuracy • Proteomics, transcriptomics, metabolomics and multi-omics all supported • Backed by a team of computational image analysis experts constantly adapting it to your needs FABIAN SVARA, Chief Executive Officer, **ariadne.ai**
13:10	LUNCH BREAK & REFRESHMENTS	1-2-1 Meetings x3	Poster Displays		
	Track Chair: CHRISTIAN RUIZ, Chief Scientific Officer, MoonlightAI	**Track Chair:** MALLESWARI CHALLAGUNDLA, Lab Head, AbbVie	**Track Chair:** MARINE GARRIDO, Global Translational Lead, Bayer	**Track Chair:** KATY VANDEREYKEN, Research Manager, KU Leueven	**Track Chair:** HAITHAM SHABAN, Research Group Leader, University of Geneva
14:10	**Ultrasensitive ISP Assays To Decipher The Tumor Microenvironment: From Tissue To High-Quality Spatial Insights** • At Ultivue, we work to get scientists to better insights, faster. We allow scientists to See More, See Faster, See In Situ • ISP Ultrasensitive Assays allow scientists to see more, not only through multiplex panels - but multiplex panels that leverage a proprietary signal amplification to detect biomarkers with high sensitivity & high dynamic range • See faster through pre-validated panels & See In Situ through STARVUE spatial analysis platform ANGELA VASATURO, Director of Scientific Affairs **Ultivue**	**A Novel Next-Generation Sequencing Assay For The Identification Of BCR: ABL1 Transcript Type & Accurate & Sensitive Detection Of TKI-Resistant Mutations** • The clinical management of chronic myeloid leukemia (CML) patients requires the identification of the type of BCR::ABL1 transcript at diagnosis and the monitoring of its expression and potential tyrosine kinase inhibitor (TKI) resistance mutations during treatment. Detection of resistant mutation requires transcript type-specific amplification of BCR: ABL1 from RNA ANDREW ROCHE, Senior Director of Scientific Affairs, **ICON Laboratory Solutions**	**Multi-Omics Profiling With Untargeted Proteomics For Blood-Based Early Detection Of Lung Cancer** • We [PrognomiQ] conducted an unbiased multi-omic study of 2513 subjects, including untargeted proteomics, which demonstrated 89% and 80% sensitivity for all-stage and stage I, lung cancer, respectively, at 89% specificity in a holdout set of 392 subjects? BRUCE WILCOX, Chief Technology Officer, **PrognomiQ**	**Mapping The Unseen: Finding New Connections With Spatial Multiomics** • The MACSima™ Platform revolutionizes spatial biology with automated cyclic immunofluorescence, enabling same-section multiomic analysis • Its new RNAsky® assay detects hundreds of proteins and dozens of RNA targets in a single tissue section, providing deep insights into tissue heterogeneity and biological processes • This end-to-end solution, opens up new possibilities for studying complex tissues, like the tumor microenvironments (TME) with unprecedented precision. Enabling scientists to advance immuno-oncology research like never before KATRIN SCHÖNBORN, Global Product Manager for Spatial Biology Application, **Miltenyi Biotec**	*Delegates Are Welcome To Attend The Co-Located Sessions*

3RD ANNUAL BIOMARKERS EUROPE CONGRESS

2ND ANNUAL PRECISION ONCOLOGY EUROPE CONGRESS

3RD ANNUAL SPATIAL BIOLOGY EUROPE CONGRESS

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT

CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

CONFERENCE ROOM 3: MULTI-CANCER EARLY DETECTION TECHNIQUES & COMPANION DIAGNOSTICS FOR PRECISION ONCOLOGY

CONFERENCE ROOM 4: SPATIAL MULTI OMICS TECHNIQUES & APPROACHES

CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING & DIGITAL PATHOLOGY FOR SPATIAL BIOLOGY

14:35

Multi-Omic Biomarkers In Clinical Development And Rare Diseases

- Why is one biomarker is often not enough?
- What are the limitations and opportunities in (ultra-)rare diseases?
- How can we collaborate to achieve better and faster solutions?

THOMAS HACH, Senior Clinical Development Medical Director, **Novartis**

Blood Biomarker Challenge

- Two grants have been awarded this year to push forward the adoption of blood biomarkers into clinical practice
- The Biomarker Factory, which I run, is involved in both

AMANDA HELSGRAVE, Senior Research Fellow, **University College London**

Closed Door Workshop: Advancements In Liquid Biopsy Technologies For Precision Oncology

Presentation 1: Circulating Tumor DNA As A Key Biomarker For Oncology Phase I Clinical Drug Development

- Circulating tumor DNA (ctDNA) is increasingly used for screening, diagnosis, and management of advanced/metastatic cancers, with approved assays now guiding patient management
- Despite its potential, ctDNA analysis is underutilized in Phase I clinical trials, where it could enhance patient selection, dose optimization, and drug mechanism proof
- Use of cost-effective genome-wide & methylation based methods to integrate ctDNA more systematically into early phase clinical trials

NOLWEN GUIGAL- STEPHAN, Head of Clinical Biomarkers, **Servier**

Presentation 2: Reporting Molecular Findings Of ctDNA Analysis In Pathology: ELBS Guideline

- NGS analysis of plasma-derived ctDNA results in molecular findings different from those observed in diagnostic tissue NGS analysis
- How to report low-copy variants (e.g. VAF <0.1%)
- How to report negative results & the role of CHIP

ED SCHUURING, Clinical Scientist in Molecular Pathology, **University Medical Centre Groningen**

Presentation 3: Liquid Biopsies In Solid Tumors - Applications & Utility In Clinical Drug Development & Real-World Setting

- Liquid Biopsy applications (e.g. selecting patients for personalized treatment options, monitoring molecular response, identifying aquired resistance mechanism) in selected solid tumor indications (e.g. NSCLC, melanoma)
- Value of utilizing liquid biopsies in clinical drug development and real-world setting, as well as remaining challenges

JAN CHRISTOPH BRASE, Translational Science Leader, **Bayer**

Workshop: Applications Of Spatial Metabolomics

Presentation 1: Deep MALDI-MS Spatial Omics Guided By Quantum Cascade Laser Mid-Infrared Imaging Microscopy

- Using deep MALDI-MS spatial omics
- Applications within metabolomic studies

CARSTEN HOPF, Professor, **Mannheim University**

Presentation 2: Spatial Lipidomics And Multi-Omics Applications In Oncology

- Potential of spatial lipidomics and related multi-omics approaches to map alterations in lipid metabolism in complex human tumors and to uncover exploitable targets for antineoplastic therapy

JOHAN SWINNEN, Professor, **KU Leuven**

Panel Discussion: Applications Of Spatial Metabolomics

- How to link spatial metabolomics with spatial proteomics
- Industrial perspectives
- Imaging mass spectrometry
- Chip cytometry
- Characterizing spatial heterogeneity

Moderator: CARSTEN HOPF, Professor, **Mannheim University**

Panellists:

JOHAN SWINNEN, Professor, **KU Leuven**

DENIS SCHAPIRO, Group Leader, **Heidelberg University Hospital**

Panel Discussion:
Exploring The Potential Of AI & Image Analysis In The Development Of Spatial Biology Research

- Applications in transcriptomic studies
- Image analysis workflows
- AI-powered biological insights

Moderator
B. DUSTY MAJUMDAR, Chief Executive Officer, **PredxBio**
Panellists:
MERRICK STROTTON, Principal Scientist, **UCB**

MATTHEW HUMPHRIES, Director of Research Operations, **Leeds Teaching Hospitals NHS Trust**

ZEINAB MOKHARTI, Scientific Investigator, **GSK**

FILIPPO PULLARA, Chief Scientific Officer, **PredXBio**

15:00

Closed Door Panel Discussion: Challenges In Translating Exploratory Biomarkers Into The Clinic

- Challenges of translating some of initial findings into something more robust
- How does proteomics feature in target discovery?
- Clinical utility & validation
- The role of biomarkers evolving in the context of precision medicine

Moderator:
KEVIN VERVIER, Associate Director of Data Science, **Novartis**

Panellists:

JUN FREDERIKSEN, Director of Omics Technologies, **NovoNordisk**

OLGA NISSAN, Chief Scientific Officer, **Protica Bio**

Harnessing Biomarkers To Accelerate Success Of Early Drug Development: Case Example Of A Phase 1 Study Of MP0317 (FAP x CD40 DARPin) In Solid Tumors

- A Phase 1 dose-escalation study of MP0317 (NCT05098405), a bispecific DARPin designed for tumor-localized CD40-mediated immune activation with improved safety compared to systemic CD40 agonistic approaches
- MP0317 targets the tumor microenvironment via binding to fibroblast activation protein (FAP)
- The assessment of tumor and peripheral biomarkers was crucial for confirmation of the desired mechanism of action, support the monitoring of safety parameters, and definition of a dose range for further clinical development

VAIA STAVROPOULOU, Clinical Biomarker Lead, **Molecular Partners**

15:25

A Composite Decision Rule Of CD8+ T-cell Density Predicts Efficacy In Early-Stage, Immunotherapy Trials

- We examined whether CD8+ T-cell numbers in paired tumor biopsies could serve as early indicators of clinical benefit in cancer immunotherapies
- Increased CD8+ T-cell density correlated with prolonged progression-free survival. A composite score determined what CD8+ T-cell density may serve as a biomarker for clinical outcomes in early trials

JEHAD CHARO, Biomarker & Experimental Medicine Leader, **Roche**

Delegates Are Welcome To Attend The Co-Located Sessions

	3RD ANNUAL BIOMARKERS EUROPE CONGRESS		2ND ANNUAL PRECISION ONCOLOGY EUROPE CONGRESS	3RD ANNUAL SPATIAL BIOLOGY EUROPE CONGRESS	
	CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3: MULTI-CANCER EARLY DETECTION TECHNIQUES & COMPANION DIAGNOSTICS FOR PRECISION ONCOLOGY	CONFERENCE ROOM 4: SPATIAL MULTI OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING & DIGITAL PATHOLOGY FOR SPATIAL BIOLOGY
15:50	AFTERNOON BREAK	1-2-1 Meetings x3	Poster Displays	Company Spotlights x6	
16:50	**Improving Biomarker Discovery With Clinical Trial Omics** • Results from our "backtranslation effort" - a retrospective analysis, benchmarking pre-clinical biomarker candidates with omics data from large clinical trials • Comparing various omic types, shortlisting approaches and experimental study designs, we identify the preclinical features most predictive of biomarker success in late phase cardiometabolic studies • A data-driven framework to evaluate biomarker selection strategies and to extract general principals of biomarker translation DANIEL KEITLEY, Research Scientist, **Novo Nordisk**	**Biomarker Assay Development & Therapeutic Application** • The need for advanced technologies in biomarker assay development • Developing homebrew assays using highly sensitive platforms • Key parameters and quality considerations • Addressing matrix effects in complex matrices • Standard timeline for homebrew assay development MALLESWARI CHALLAGUNDLAY, Laboratory Head, QTAS_Biomarkers, **Abbvie**	**Workshop: Advancements In Liquid Biopsy Technologies For Precision Oncology (Cont.)** **Panel Discussion: Applications Of Liquid Biopsy Techniques In Precision Oncology** • Explore the role of liquid biopsy in tailoring precision medicine approaches for individual cancer patients • Overcoming current challenges and limitations associated with biopsy techniques • Exploring tumor heterogeneity **Moderator:** PHILIP BEER, Chief Scientific Officer, **Step Pharma** **Panellists:** ED SCHUURING, Clinical Scientist in Molecular Pathology, **University Medical Cantre Groningen** JAN CHRISTOPH BRASE, Translational Science Leader, **Bayer** DANA MUSTAFA, Assistant Professor & Group Leader, **Erasmus University Medical Center**	nanoString A BRUKER COMPANY **NanoString Workhop: High-Plex Spatial Multiomics: Unveiling The Hidden Dimensions of Cellular Complexity** **Presentation 1: Advancements In Tissue Digital Spatial Profiling & Single Cell Spatial Molecular Imaging** CHRISTOPH KOENIG, Principal Research Scientist, **Bruker Spatial Biology** **Presentation 2: SARIFA, Tumor-Adipocyte Interaction & Spatial Gene & Protein Expression** NIC REITSAM, Pathologist, Faculty of Medicine, **University of Ausburg** **Presentation 3: Wounding Triggers Invasive Progression In Human Basal Cell Carcinoma** MASSIMO ANDREATTA, Senior Researcher, Department of Oncology, **University of Lausanne**	*Delegates Are Welcome To Attend The Co-Located Sessions*
17:15	**Digital Biomarker Case Study** • Novel digital health tools • Leveraging clinical biomarkers as digital endpoints in clinical research SACHIN SHAH, Digital Biomarker Lead, **GSK**	*Delegates Are Welcome To Attend The Co-Located Sessions*			

3RD ANNUAL BIOMARKERS EUROPE CONGRESS

2ND ANNUAL PRECISION ONCOLOGY EUROPE CONGRESS

3RD ANNUAL SPATIAL BIOLOGY EUROPE CONGRESS

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT

17:40

Roundtable Discussion 1: Do Biomarkers Need To Biologically Plausible?

- Challenges in establishing biological plausability
- Translational research & clinical utility
- Clinical validation & reproducibility

Moderator: JUN FREDERIKSEN,Director of Omics Technologies, **Novo Nordisk**

Roundtable Discussion 2: Clinical Utility, Validation, & Collaborations In Clinical Trials

Moderator: OLGA NISSAN, Chief Executive Officer, **Protica Bio**

18:05

CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

Delegates Are Welcome To Attend The Co-Located Sessions

CONFERENCE ROOM 3: MULTI-CANCER EARLY DETECTION TECHNIQUES & COMPANION DIAGNOSTICS FOR PRECISION ONCOLOGY

Roundtable Discussion 1: What Makes A Good Companion Diagnostic?

- Biomarker selection
- Analytical validity & performance
- Integration with therapeutic development

Moderator PHILIP BEER, Chief Scientific Officer, **Step Pharma**

Roundtable Discussion 2: Regulation Of Biomarkers

- IVDR regulations
- Understanding the authories needs

Moderator: MAXIMILIAN BREITNER, Lab Head Clinical Bioanalysis, **Sandoz**

CONFERENCE ROOM 4: SPATIAL MULTI OMICS TECHNIQUES & APPROACHES

NanoString Workhop Continued:

nanoString
A BRUKER COMPANY

Panel Discussion: The Present & Future Of Spatial Multiomics

Moderator: ESPY ANGUIANO, Director, Pharma & CRO Business Strategy, **Bruker Spatial Biology**

Panellists:

CHRISTOPH KOENIG, Principal Research Scientist, **Bruker Spatial Biology**

MASSIMO ANDREATTA, Senior Researcher, Department of Oncology, **University of Ausburg**

NIC REITSAM, Pathologist, Faculty of Medicine, **University of Ausburg**

İLAYDA HASAKIOĞULLARI, Senior R&D Product Manager, **CellCarta**

BENTON BERIGAN, Product Manager Spatial Biology, **Canopy Biosciences**

KIRSTEEN MACLEAN, Principal Scientist, **Neogenomics Laboratories**

CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING & DIGITAL PATHOLOGY FOR SPATIAL BIOLOGY

Delegates Are Welcome To Attend The Co-Located Sessions

18:30 **End of Day One & Drinks Reception**

19:30 - 21:00

NETWORKING DINNERS

nanoString
A BRUKER COMPANY

10x GENOMICS

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn
@OGConferences

DAY TWO: 01 OCTOBER 2024

CONFERENCE ROOM 1: DATA DRIVEN APPROACHES FOR BIOMARKER ANALYSIS IN DRUG DEVELOPMENT

Track Chair: VINKO TOSEVSKI, Senior Director, Translational Research, Immunos Therapeutics

Track Keynote Address: How Precision Medicine Can Contribute To Data-Driven Decision Making In Drug Development

- How does data help making decisions in drug development
- The challenges of the precision medicine paradigm in modern drug development
- Some common issues encountered in day to day drug development
- Why creating a data driven precision medicine strategy is a lot more work than you thought
- An illustrative example: ctDNA

GUNTHER JANSEN, Head of Multimodal Data & Analytics, **Novartis**

08:30

Harnessing The Value Of Digital Biomarkers: Why We Need To 'Watch The Whole Movie Not Just The Trailer'

- The case for change
- Progression and defining digital biomarkers (Walk, talk, think, see and feel)
- What challenges might lie ahead?

DYLAN POWELL, Assistant Professor in Public Health & Innovation, **University of Stirling**

08:55

Modeling Cellular Networks In Single-Cell & Spatial Data

- We have developed a unified framework to unravel cellular networks from single-cell and spatial data
- We will illustrate this network with applications to spatial/single-cell breast cancer data and to a comparison of single-cell transcriptomic and proteomic data

JACQUES COLINGE, Professor, **University of Montpellier**

CONFERENCE ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT & PERSONALISED PATIENT TREATMENT

Track Chair: SINA NASSIRI, Principal Bioinformatics Scientist & Team Lead, Roche

Track Keynote Address: Want To Make Precision Medicine A Reality? Time To Rethink The Way We Develop Drugs!

- Biomarkers play a bigger and bigger role in drug development, but which are these roles?
- Precision medicine (PM) randomised controlled trials (RCTs) aim to demonstrate differential clinical efficacy for specific endophenotypes
- Many sites participate in multiple RCTs simultaneously. Is there any impact of competing for the same patients on the statistical power of non-PM studies?
- If we want to see the realisation of precision medicine, shall we revisit the way our industry develops drugs?

GUILLAUME DESACHY, Head Of Biometrics, **Pierre Fabre**

Translational Omics Innovations To Drive Personalized Health(care)

- Multi-omics is a powerful approach to map human biology
- Strong potential to boost personalized health and healthcare
- Stringent workflows needed to translate discovery to clinical application
- Promising developments in oncology and rare inherited diseases will be highlighted

ALAIN VAN GOOL, Professor of Personalized Healthcare, **Radboud University Medical Centre**

Coping With Project Optimus In Small Biopharma

- A traditional maximum tolerated dose approach to the development of small molecules and biologics in cancer is often not appropriate
- The FDA's Project Optimus is a timely intervention to change the way modern oncology drugs are developed
- However, Optimus brings significant additional burdens, especially for small biopharma
- This talk will explore ways in which the upsides of Optimus can be maximised whilst the downsides mitigated

PHILIP BEER, Chief Scientific Officer, **Step Pharma**

CONFERENCE ROOM 3: SPATIAL BIOINFORMATICS, DATA ANALYTICS AND INTERPRETATION

Track Chair: IVAN COSTA, Professor, Aachen University

ThermoFisher Scientific Workshop: Advancing Imaging Tools For Spatial Proteomics

Presentation 1: Navigating Challenges In Spatial Proteomics From An Imaging Core Facility Perspective

- High, medium and low plex
- Planning, every step counts
- Experience with the EVOS S1000 Imaging System

CAROLINA OSES SEPÚLVEDA, Lab Manager, **SciLifeLab**

Presentation 2: Addressing Proteomics Multiplex Imaging Challenges With The Invitrogen™ EVOS™ S1000 Spatial Imaging System

- Insights into current challenges faced by multiplex fluorescence methods
- How can spectral technologies help scientists overcome some of these challenges
- The new EVOS S1000 Spatial Imaging System: spectral simplicity for spatial proteomics imaging

ADYARY FALLERERO, Senior Product Manager **ThermoFisher Scientific**

Presentation 3: An Introduction To Invitrogen™ Aluora™ Spatial Amplification Reagents

- Considerations for multiplex detection for tissue imaging
- Signal detection strategy in spatial proteomics
- Reagents and workflows

EDWARD PARKIN, Product Manager, **ThermoFisher Scientific**

CONFERENCE ROOM 4: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY

Track Chair: ASAD JAN, Assistant Professor, Aarhus University

Track Keynote Address: Spatial Biology To Understand The Immune Landscape

- The role of spatial biology in mapping the immune landscape
- Bringing spatial biology into translational research

STÉPHANIE TISSOT, Head of Immune Landscape Laboratory, **Centre Hospitalier Universitaire Vaudois**

Workshop: Spatial Identification Techniques To Advance Therapeutics

Presentation 1: Identifying Biomarkers Of Response To Immunotherapy With Spatial Biology

- How spatial biology can improve identification of biomarkers of response
- Case studies from immunotherapy

RAPHAEL GOTTARDO, Professor & Director, **Centre Hospitalier Universitaire Vaudois**

Presentation 2: From Oncology To Cardiology: Spatial Omics Technologies For Topographic Biomarker Discovery

- Spatial omics experimental design strategies and analysis in the context of oncology & cardiology

DENIS SCHAPIRO, Group Leader, **Heidelberg University Hospital**

CONFERENCE ROOM 1: DATA DRIVEN APPROACHES FOR BIOMARKER ANALYSIS IN DRUG DEVELOPMENT

09:20

Panel Discussion: The Latest Advances In Multi-Omics Approaches For Biomarker Analysis, Data Analysis & Integration Into The Clinic

- The role of AI/ML tools in overcoming challenges in analyzing large- scale multi- omics datasets
- Multi- omics for diagnostics, prognosis and treatment strategies

Moderator

VOLODIMIR OLEXIOUK, Director Scientific Engangment, **BioLizard**

Panellists:

GUNTHER JANSEN, Head of Multimodal Data & Analytics, **Novartis**

VINKO TOSEVSKI, Senior Director, Translational Research, **Immunos Therapeutics**

09:45

SINA NASSIRI, Principal Bioinformatics Scientist & Team Lead, **Roche**

RANGANATH GUDIMELLA, Bioinformatics Scientist, **TRON Mainz**

Computational Pathology: Towards Precision Medicine

- Recent results from our research employing digital pathology across the oncology, cardiac, and nephrology domains. Applications include those of diagnosis, and prediction of prognosis and therapy response.
- How the utilization of deep learning in these domains is significantly improving the efficiency and robustness of these tools

10:10

- Translation to clinical settings requires dedicated efforts and some experiences are discussed
- Remaining challenges including: quality control and annotation gathering
- Introduction to our open-source tools being developed and deployed to meet these pressing needs, including HistoQC and Quick Annotator, and PatchSorter

ANDREW R. JANOWCZYK, Assistant Professor, **Emory University**

10:35

MORNING COFFEE & REFRESHMENTS

1-2-1 Meetings x4

Poster Displays

Applications of Single-Cell & Bulk Adaptive Immune Receptor Profiling for Drug Target & Biomarker Discovery

- Learn how Cellecta's highly sensitive and reproducible DriverMap AIR technology is enabling novel insights in the lab and speeding up target discovery and validation workflows.

11:55

ALEX CHENCHIK, President & Chief Scientific Officer, **Cellecta, Inc**

CELLECTA

CONFERENCE ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT & PERSONALISED PATIENT TREATMENT

Closed Door Panel Discussion: How To Bridge The Gap Between The Bench & Bedside: Applications of Precision Medicine In A Healthcare Setting

- What do we mean by precision medicine?
- Challenges & opportunities
- Future directions

Moderator

DANA MUSTAFA, Assistant Professor & Group Leader, **Erasmus University Medical Center**

Panellists:

GUILLAUME DESACHY, Head of Biometrics, **Pierre Fabre**

DYLAN POWELL, Professor in Public Health & Innovation, **University of Stirling**

ALIYA SARMANOVA, Clinical Development Lead Oncology & Genetics, **Roche Diagnostics International**

ALAIN VAN GOOL, Professor of Personalized Healthcare, **Radboud University Medical Centre**

Drug Response Prediction Using A Multi-Gene mRNA Biomarker Approach

- By analysing gene expression in cancer cell lines that are sensitive and resistant to a cancer drug, Allarity has developed drug-specific response predictors
- Clinical validation for several responsepredictors

THOMAS JENSEN, Chief Executive Officer, **Allarity**

Photonic Diagnostics Platform: A Multimodal Point-of-Care Solution With Lab-Grade Precision

- The Surfix Photonic Diagnostics Platform combines photonics, nanocoatings, and microfluidics to deliver fast, affordable, and accurate multimodal testing
- It enables point-of-care diagnostics outside the lab, addressing complex diseases with lab-grade precision

NADIEH KUIJPERS, Chief Commercial Officer **Surfix Diagnostics**

SURFIX diagnostics

CONFERENCE ROOM 3: SPATIAL BIOINFORMATICS, DATA ANALYTICS AND INTERPRETATION

Panel Discussion: Spatial Imaging For Tissue Samples & Protein Expression

Panellists

EDWARD PARKIN, Product Manager, **ThermoFisher Scientific**
ADYARY FALLERERO, Senior Product Manager **ThermoFisher Scientific**
CAROLINA OSES SEPÚLVEDA, Lab Manager, **SciLifeLab**

ThermoFisher SCIENTIFIC

Multi-Scale Approaches For Patient Level Analysis Of Spatial Transcriptomics Data

- Multiscale computational methods to find groups of patients sharing similar molecular and cellular niches signatures
- Application of these approaches in spatial transcriptomics data from kidney and heart disease

IVAN GESTEIRA COSTA FILHO, Professor of Computational Genomics, **University of Aachen**

Computational Algorithms For Spatial Analysis

- Primary challenges and computational facets associated with downstream algorithms in the analysis of spatial transcriptomics

ROSALBA GIUGNO, Professor, **University of Verona**

Tumor-Specific MHC Class II Upregulation Associated With Response To Anti-PD-L1 Therapy In Patients With Urothelial Cancer

- How CellCarta is utilizing GeoMx to validate tumor-specific MHC Class II upregulation as a biomarker in urothelial cancer

İLAYDA HASAKIOĞULLARI, Senior R&D Product Manager, **CellCarta**

nanoString A BRUKER COMPANY

CONFERENCE ROOM 4: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY

Presentation 3: Molecular Signatures Of Altered Energy Metabolism And Circadian Rhythm Perturbations In A Prion-Like Model Of Synucleinopathy

- Spatial transcriptomics was applied for studying the molecular signatures of early and advanced alpha-synuclein pathology in context of Parkinson disease
- The data implicate progressive defects in energy metabolism, ribosomal translation, cellular protein transport and immune response

ASAD JAN, Assistant Professor, **Arhus University**

Panel Discussion:

- Spatial biology for biomarker and target identification
- Challenges and limitations across various therapeutic areas

Moderator:

BYRON HARTMAN, Senior Staff Product Manager, **10x Genomics**

Panellists:

RAPHAEL GOTTARDO, Professor & Director, **Centre Hospitalier Universitaire Vaudois**

DENIS SCHAPIRO, Group Leader, **Heidelberg University Hospital**

ASAD JAN, Assistant Professor, **Arhus University**

KATY VANDEREYKEN, Research Manager, **KU Leuven**

Spatial Molecular Imaging In Colon Cancer

- Spatial molecular imaging provides a robust calling of various cell types within the tumor microenvironment at the invasive front of colon adenocarcinomas and within adjacent normal tissues
- The spatial localization of epithelial cells corresponds to areas of pan-Cytokeratin immunofluorescence staining
- Individual cancer clones, which were called solely based on their gene expression patterns, were located together as would be expected if their evolution is resulting from mutations or epigenetic changes on which natural selection acts, favoring the expansion of advantageous heritable changes

LASSE KRISTENSEN, Associate Professor & Group Leader, **Aarhus University**

Spatial Immune Cell Distribution In Tumors To Categorize Patients

- The tumor microenvironment (TME) is a dynamic entity that is continuously shaped by a multitude of stimuli, including diverse cells and molecules. Its composition includes tumor cells, endothelial cells, fibroblasts, and a diverse range of immune cells. The TME is known to modify the response to treatment. It has been demonstrated that the immunosuppressive characteristics of the TME weaken the anit-tumor immune responses, hence, modifications in the TME can impact the outcomes of treatment. As such, as more accurate understanding of the TME is crucial for classifying patients into several subgroups. While techniques such as spectral flow cytometry enable comprehensive analysis of the phenotypic and functional properties of immune cells in tumors, they do not provide information about the spatial ditribution of these cells. We therefore employed spectral flow cytometry alongside multiplex imaging with Cell DIVE to classify pleural mesothelioma samples into three unique subgroups. Additionally, we compared two approaches for evaluating patient outcomes.

ANURAG GUPTA, Lab Head & Lecturer, **University of Fribourg**

Leica MICROSYSTEMS

CONFERENCE ROOM 1: DATA DRIVEN APPROACHES FOR BIOMARKER ANALYSIS IN DRUG DEVELOPMENT	CONFERENCE ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT & PERSONALISED PATIENT TREATMENT	CONFERENCE ROOM 3: SPATIAL BIOINFORMATICS, DATA ANALYTICS AND INTERPRETATION	CONFERENCE ROOM 4: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY
12:20 **Blood Based Biomarkers Of Alzheimer's Disease: The Power Of Polyclonal Antibodies** • Tau based blood biomarkers of Alzheimer's disease are shaping up to be the future of Alzheimer's disease diagnosis. However, current assays overlook the numerous proteolytic cleavage sites of the tau protein, potentially missing critical information from smaller fragments, generated by over 60 proteolytic cleavage sites • By capturing a broader range of tau species, a polyclonal approach may offer valuable insights for disease progression. This has the potential to enable disease staging and differentiate between tauopathies MOHAMMAD ARASTOO, Research Fellow, **University Of Aberdeen**	**Personalised Therapeutic Vaccines In Oncology** • Therapeutic vaccination for cancer treatment has not been successful for decades, the main issue being antigen selection • Recent clinical trials results however suggest that therapeutic vaccination might be the next cancer drug class to market • Most encouraging results are reported with virus-targeting vaccines and personalized vaccination CHRISTOPHE LE TOURNEAU, Professor, **Curie Insitute**	**Quantitively Characterising Developmental Reproducibility In Embryos Across Spatial And Temporal Scales** • How does natural variability impacts embryonic development and species adaptation? To answer this question we work on the following methods: • Algorithms to quantify cell morphodynamics across spatial and temporal scales and across multiple species • We also develop algorithms to integrate and visualise spatial omics methods in space • Overview of all these methods and their usage LÉO GUIGNARD, Group Leader, **Aix-Marseille Université & CNRS, Institut of Developmental Biology of Marseille & Turing Centre**	**Quantitative 3D Microscopy Of Hematopoietic Stem Cell Niches** • Dissecting the cellular make-up of hematopoietic tissues to understand how stromal components interact with blood cells and contribute to the regulation of bone marrow hematopoietic function and hematopoietic stem cell maintenance in health and disease • Developed 3D microscopy techniques that allow us to visualize all the tissue components in situ, observe their structural changes and define the spatial affinities between them, which can teach us about their functional crosstalk CÉSAR NOMBELA-ARRIETA, Associate Professor & Group Leader, **University Hospital Zurich**
12:45 **FIGARO-BM, A Biomarker Study Of FIGARO-DKD, Reveals New Insights Into The Mode-Of-Action Of Finerenone** • The FIGARO-BM study explored the pharmacodynamic response of finerenone, a non-steroidal MR antagonist. Analysis of 2941 plasma biomarkers support that finerenone acts on inflammation and fibrosis pathways, offering insights into its clinical benefits in cardiorenal patients MARIO BERGER, Senior Biomarker Strategist, **Bayer AG** Olink®	*Delegates Are Welcome To Attend The Co-Located Sessions*	**High-Plex Whole Slide Spatial Biology Assays Powered By The Hyperion XTi** • Introducing the Hyperion XTi, a revolutionary Imaging Mass Cytometry System. Ultra-fast whole slide imaging and intelligent ROI selection redefine high-throughput imaging ROBERTO SPADA, Director of Global Marketing, **Standard BioTools** STANDARD BIOTOOLS	**Ultrahigh-Plex & High-Throughput Spatial Biology Solutions: From Discovery To The Clinic** • Learn how you can scale up your spatial discovery efforts and rapidly translate those discoveries into actionable spatial phenotypic signatures with Akoya's full continuum of spatial phenotyping solutions that serve the diverse needs of researchers across discovery, translational and clinical research IVAN MASETTO, Senior Field Applications Scientist, **Akoya Biosciences** AKOYA BIOSCIENCES® THE SPATIAL BIOLOGY COMPANY®
13.10	LUNCH BREAK & REFRESHMENTS · 1-2-1 Meetings x3 · Poster Displays		
14.10 **Single Site Companion Diagnostic Framework & FDA LTD Final Rule** • Learn more about the US FDA and EU IVDR frameworks involved in the development of a companion diagnostic including regulatory and collaboration strategies for efficient development, FDA and IVDR regulatory insights, and the evolving US LDT landscape TODD CHERMAK, Senior Vice President & Global Business Head Immunology & Proteomics, **CellCarta** CellCarta	**Identifying Candidate Biomarkers That Reflect Disease State & Response To The NETosis Targeting Therapeutic CIT-013** • Citryll's clinical development candidate CIT-013 inhibits the release of neutrophil extracellular traps (NETs) • Introducing the Hyperion XTi, a revolutionary Imaging Mass Cytometry System. Ultra-fast whole slide imaging and intelligent ROI selection redefine high-throughput imaging SIJRANKE POST, Scientist, Project Manager, **Ardena** ARDENA	*Delegates Are Welcome To Attend The Co-Located Sessions*	**Spatial Cytometry: Mapping The Universe At Single-Star Resolution** CORALIE GUERIN, Head of Cytometry, **Institute Curie** RARECYTE®

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn
@OGConferences

CONFERENCE ROOM 1: DATA DRIVEN APPROACHES FOR BIOMARKER ANALYSIS IN DRUG DEVELOPMENT

Unbiased & Targeted Proteomics For Translational & Clinical Research

- Biognosys is a world leader in MS proteomics, serving the drug discovery community
- In this talk, Ben will outline the use of Biognosys' platforms in translational and clinical research, including custom panels for pharmacokinetic analysis and proteome profiling for biomarker discovery

BENYAHIA CHEBEL, Business Development Manager - Europe,
Biognosys

BIOGNOSYS
NEXT GENERATION PROTEOMICS

Delegates Are Welcome To Attend The Co-Located Sessions

CONFERENCE ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT & PERSONALISED PATIENT TREATMENT

Global AI-Enabled Pathologists Network: A New Era in Clinical Trials

- Diagnexia Analytix stands at the forefront of revolutionising pathology services for clinical trials, addressing critical challenges with innovative solutions
- Diagnexia's integrated platform facilitates rapid pathology reviews, enhances collaborative research, and ensures seamless data integration
- By bridging the expertise gap with a team of expert pathologists, Diagnexia Analytix accelerates the development of complex studies, emphasising speed, accuracy, and reliability
- Diagnexia's comprehensive service offerings span across key disease areas, making Diagnexia Analytix a pivotal partner in advancing clinical research with precision and expertise

PIERRE MOULIN, Chief Scientific Officer,
Diagnexia

DIAGNEXIA ANALYTIX

Delegates Are Welcome To Attend The Co-Located Sessions

CONFERENCE ROOM 3: SPATIAL BIOINFORMATICS, DATA ANALYTICS AND INTERPRETATION

Delegates Are Welcome To Attend The Co-Located Sessions

Panel Discussion: Overcoming The Challenges Of Spatial Data Integration

- Normalizing data at the same level for integration
- Combining spatial & sequencing based data
- User & beginner perspectives of spatial technologies
- How to infer gene expression from different sequencing datasets

Moderator:

ZEINAB MOKHARTI, Scientific Investigator, **GSK**

Panellists:

RAPHAEL GOTTARDO, Professor & Director, **Centre Hospitalier Universitaire Vaudois**

OLIVER BIEHLMAIER, Head of Imaging Core Facility, **University of Basel**

ESPY ANGUIANO, Director, Pharma & CRO Business Strategy, **Bruker Spatial Biology**

Assessing Crosstalk Between Spatial Transcriptional Programs And Tissue Stiffness In Colon Cancer

- Tumor stiffness is known to associate with disease progression in certain cancers
- We have established methods to assess colon tumor stiffness combining atom force-macroscopy and statistical modeling
- We found associations with stroma, laterality, age, and RAS mutations
- Recently, we added spatial transcriptomics data to try unraveling biological pathways associated with stiffness

JACQUES COLINGE, Professor,
University of Montpellier

Integrating Spatial-Omics In A Microscopy Core Facility

- Integration of Spatial Biology: Report from the implementation of a Vizgen Merscope system for spatial transcriptomics at the Imaging Core Facility of the Biozentrum in Basel
- Challenges and Considerations: planning for lab space, operational costs, data storage, image processing, high-performance computing infrastructure and knowledge for spatial omics
- Guidance for Selection: The presentation aims to provide guidance on choosing the most suitable spatial biology solution based on individual research needs and objectives

OLIVER BIEHLMAIER, Head of Imaging Core Facility,
University of Basel

CONFERENCE ROOM 4: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY

PD-1/PD-L1 Functional Engagement Quantified By QF-Pro® In NSCLC Is A Strong Predictor Of Immune Checkpoint Inhibitors Response

- QF-Pro® - the spatial biology platform of HAWK Biosystems, quantifies PD-1/PD-L1 interaction states within FFPE biopsy samples from patients and can better stratify patients to receive these therapies
- In a study of 188 NSCLC patients, QF-Pro® demonstrated there was no correlation between the extent of PD-1/PD-L1 interaction and PD-L1 expression. Moreover, PD-1/PD-L1 interaction state, but not PD-L1 TPS scores, was predictive of treatment response. This relationship was particularly strong in in first line treatments and was also observed in PD-L1 negative (<1%) patients
- QF-Pro® identifies a subset of patients who, with low PD-L1 TPS scores are not routinely prescribed these therapies. However, QF-Pro® detected that, despite this low expression, these patients exhibit a strong PD-1/PD-L1 interaction state and therefore response strongly to these therapies. This identifies a platform that has the ability to triple response rates to these drugs and double overall survival rates

JAMES MILES, Product Manager,
Hawk Biosystems

HAWK Biosystems

Panel Discussion: Exploring The Application Of Spatial Technologies In Immunology & Oncology

- Spatial molecular imaging in immunology & oncology
- Challenges & limitations of spatial translation towards the clinic
- Making spatially targeted therapeutics more precise

Moderator:

BENTON BERIGAN, Product Manager Spatial Biology, **Canopy Biosciences**

Panellists:

STÉPHANIE TISSOT, Head of Immune Landscape Laboratory, **Centre Hospitalier Universitaire Vaudois**

HANNAH WILLIAMS, Junior Group Leader, **University of Bern**

SEMIRAMIS POPOVA, Senior Scientist,
AstraZeneca

Spatial Multi-Omics For Translation Research: Colorectal & Pancreatic Cancer

- This talk will explore paradigms for the translational application of spatial omics modalities with a pathology focus
- Top-down" approach with example using multiplex immunofluorescence for pancreatic ductal adenocarcinoma
- Bottom-up" approach with example using spatial transcriptomics to examine tumour budding in colorectal cancer

HANNAH WILLIAMS, Junior Group Leader, **University of Bern**

Unlocking Immune Subpopulations Through Spatial Multi-Omics

- Utilising spatial multi-omics to characterise immune cell population dynamics and molecular signatures
- Leveraging multimodal platforms to analyse treatment responses and disease progression
- Advancing beyond single-cell technologies to understanding cell organisation and interactions

SEMIRAMIS POPOVA, Senior Scientist,
AstraZeneca

14.35

15:00

15.25

15:50

16:15

End of Congress

VENUE INFORMATION

Be Part of Something Exceptional

Congress Center Basel

MCH Swiss Exhibition (Basel) Ltd.
Messeplatz 21, CH-4058 Basell

By Rail

Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)

By Tram

From the SBB/SNCF railway station, it's a ten-minute journey on the No. 1 or 2 Tram to the "Messeplatz/Exhibition Square" stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, "Messeplatz/Exhibition Square" is the second stop on the No. 2 or 6 tram.

By Air

EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport's No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/ Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/

By Car

Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The "Messe" exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.



Please **click here to visit the venue's website** & to recieve more information on Congress Center Basel

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Your Gateway to a Year of Unparalleled Knowledge-Sharing, Curated Experiences, and Global Networking!

Welcome to the future of life sciences engagement!

Effortless On-Demand Presentations

Immerse yourself in competitor case studies, groundbreaking market developments, and captivating high-level strategy discussions via our comprehensive library of on-demand presentations.

Beneficial Partnerships and Accelerated Learning

Foster invaluable partnerships for your business and accelerate high-end learning through peer-to-peer interactions. Participate in regular science exchange sessions, engaging group discussions, and dynamic in-person and online events that drive professional growth.

Year-Round Exclusive Insights

Unlock a world of exclusive insights throughout the year via our online platform. Enjoy unrestricted access to commentaries, interviews with Key Opinion Leaders (KOLs), industry reports, and curated market intelligence content, keeping you at the forefront of industry trends.

Featuring content & recordings from all Oxford Global brands:

- BIOLOGICS
- BIOMARKERS
- CELL & GENE
- DISCOVERY
- FORMULATION & DELIVERY
- IMMUNO
- OMICS

Digital Pass

£459 +VAT

$700 +VAT

Register Now

To receive bespoke proposal for group packages contact us at pluspass@oxfordglobal.com

BROCHURE CONTENTS

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn

@OGConferences

BIOMARKERS SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.

Biomarkers Europe 2024
30 September - 01 October 2024
Basel, Switzerland

Biomarkers & Immuno US 2024
28 - 29 October 2024
San Diego, USA

Multi-Omics in Biomarker Discovery & Precision Medicine: Online Symposium
12 November 2024 | GMT (UTC+0)

Biomarkers 2025
February 2025
London, UK

Biologics Series
Proteins & Antibodies | Peptides| Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Cell & Gene Series
Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Discovery Series
Organ Modelling | 3D Cell Culture
Drug Discovery Summit & Discovery Chemistry
Neuroscience Drug Development
SmartLabs Automation & Robotics

Formulation & Delivery Series
Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Immuno Series
Advances in Immuno-Oncology
Innate Killer Cells | Oncolytic Virotherapies | Targets & Cell Types in Immuno-Oncology

Omics Series
Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit www.oxfordglobal.com/calendar/ to explore our diverse portfolio of events across 2024.

OMICS SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.

NextGen Omics US 2024
21 - 22 March 2024 | Boston, USA

Synthetic Biology US 2024
21 - 22 March 2024 | Boston, USA

NextGen Omics 2024
23 - 25 October 2024 | London, UK

Synthetic Biology 2024
October 2024 | London, UK

Spatial Biology UK 2024
18 - 19 March 2024 | London, UK

Spatial Biology East Coast US 2024
10 - 11 June 2024 | Boston, USA

Spatial Biology Europe 2024
30 September - 01 October 2024
Basel, Switzerland

Spatial Biology West Coast US 2024
04 - 05 December 2024 | San Diego, USA

Biologics Series
Proteins & Antibodies | Peptides| Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Biomarkers Series
Biomarkers | Biomarker & Precision Medicine
Precision Oncology

Cell & Gene Series
Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Discovery Series
Organ Modelling | 3D Cell Culture
Drug Discovery Summit & Discovery Chemistry
Neuroscience Drug Development
SmartLabs Automation & Robotics

Formulation & Delivery Series
Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Immuno Series
Advances in Immuno-Oncology
Innate Killer Cells | Oncolytic Virotherapies | Targets & Cell Types in Immuno-Oncology

Visit www.oxfordglobal.com/calendar/ to explore our diverse portfolio of events across 2024.

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Oxford Global PLUS Pass includes unrestricted access to all events shown above and much more

Register Now

To receive bespoke proposal for group packages contact us at pluspass@oxfordglobal.com

Book Now (Biomarkers)

Book Now (Spatial Biology)

LinkedIn
@OGConferences